Low-dose DC and Infusional FU in Metastatic Gastric Carcinoma

Patients with inoperable gastric cancer may benefit from palliative chemotherapy. However, to date, there is no generally accepted standard regimen. Single chemotherapy drugs, e.g. cisplatin, 5-fluorouracil (5-FU), and doxorubicin, have long been considered as active drugs (Ajani et al., 2005), and more recently agents such as docetaxel, paclitaxel, irinotecan and oxaliplatin have been added to the list. A number of controlled studies of two-drug combination chemotherapys, especially cisplatin-containing regimen, have shown a significant improvement in median survival and quality of life compared with best supportive care (Bang et al., 2002;Ajani et al., 2003). Of these, 5-FU and cisplatin combination (FP) has been considered as an active and safe regimen for a long time (Colevas et al., 1998).